Vibrio cholerae: lessons for mucosal vaccine design

References

• Sack DA, Sack RB, Chaignat CL. Getting serious about cholera. N. Engl. J. Med.355(7), 649–651 (2006).
   PubMed Web of Science ®Google Scholar
• WHO. Cholera: global surveillance summary, 2008. Wkly Epidemiol. Rec.84(31), 309–324 (2009).
   Google Scholar
• Longini IM, Yunus M, Zaman K, Siddique AK, Sack RB, Nizam A. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J. Infect. Dis.186(2), 246–251 (2002).
   PubMed Web of Science ®Google Scholar
• Klose KE. The suckling mouse model of cholera. Trends Microbiol.8(4), 189–191 (2000).
   PubMed Web of Science ®Google Scholar
• Ujiiye A, Nakatomi M, Utsunomiya A et al. Experimental cholera in mice. 1. First report on the oral infection. Trop. Med.10, 65–71 (1968).
   Google Scholar
• Ujiiye A, Kobari K. Protective effect on infections with Vibrio cholerae in suckling mice caused by the passive immunization with milk of immune mothers. J. Infect. Dis.121, S50–S55 (1970).
   Google Scholar
• WHO. Cholera vaccines. Wkly Epidemiol. Rec.76(16), 117–124 (2001).
   PubMedGoogle Scholar
• Chaignat CL, Monti V, Soepardi J et al. Cholera in disasters: do vaccines prompt new hopes?. Expert Rev. Vaccines7(4), 431–435 (2008).
   PubMed Web of Science ®Google Scholar
• Ramamurthy T, Garg S, Sharma R et al. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet341(8846), 703–704 (1993).
   PubMed Web of Science ®Google Scholar
• Cholera Working Group ICDDR, Bangladesh. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet342(8868), 387–390 (1993).
   PubMed Web of Science ®Google Scholar
• Waldor MK, Mekalanos JJ. Vibrio cholerae O139 specific gene sequences. Lancet343(8909), 1366 (1994).
   PubMed Web of Science ®Google Scholar
• Cash RA, Music SI, Libonati JP, Snyder MJ, Wenzel RP, Hornick RB. Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J. Infect. Dis.129(1), 45–52 (1974).
   PubMed Web of Science ®Google Scholar
• Levine MM, Black RE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA. Volunteer Studies in Development of Vaccines Against Cholera and Enterotoxigenic Escherichia coli : A Review. Holme T, Holmgren J, Merson MH, Mollby R (Eds). Elsevier/North-Holland Biomedical Press, Amsterdam, The Netherlands (1981).
   Google Scholar
• Frenck RW, Clemens J. Helicobacter in the developing world. Microbes Infect.5(8), 705–713 (2003).
   PubMed Web of Science ®Google Scholar
• Nelson E, Harris J, Morris JG, Calderwood SB, Camilli A. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat. Rev. Microbiol.7(10), 693–702 (2009).
   PubMed Web of Science ®Google Scholar
• Weil AA, Khan A, Chowdhury F et al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin. Infect. Dis.49(10), 1473–1479 (2009).
   PubMed Web of Science ®Google Scholar
• Lee SH, Butler SM, Camilli A. Selection for in vivo regulators of bacterial virulence. Proc. Natl Acad. Sci. USA98(12), 6889–6894 (2001).
   PubMed Web of Science ®Google Scholar
• Rui H, Ritchie JM, Bronson RT, Mekalanos JJ, Zhang Y, Waldor MK. Reactogenicity of live-attenuated Vibrio cholerae vaccines is dependent on flagellins. Proc. Natl Acad. Sci. USA107(9), 4359–4364 (2010).
   PubMed Web of Science ®Google Scholar
• Chowdhury MI, Sheikh A, Qadri F. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991–2009. Expert Rev. Vaccines8(12), 1643–1652 (2009).
   PubMed Web of Science ®Google Scholar
• Butler SM, Camilli A. Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat. Rev. Microbiol.3(8), 611–620 (2005).
   PubMed Web of Science ®Google Scholar
• Chitnis DS, Sharma KD, Kamat RS. Role of somatic antigen of Vibrio cholerae in adhesion to intestinal mucosa. J. Med. Microbiol.15(1), 53–61 (1982).
   PubMed Web of Science ®Google Scholar
• Kirn T, Jude B, Taylor R. A colonization factor links Vibrio cholerae environmental survival and human infection. Nature438(7069), 863–866 (2005).
   PubMed Web of Science ®Google Scholar
• Kirn TJ, Taylor RK. TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups. Infect. Immun.73(8), 4461–4470 (2005).
   PubMed Web of Science ®Google Scholar
• Sperandio V, Girón JA, Silveira WD, Kaper JB. The OmpU outer membrane protein, a potential adherence factor of Vibrio cholerae. Infect. Immun.63(11), 4433–4438 (1995).
   PubMed Web of Science ®Google Scholar
• Pierce NF, Kaper JB, Mekalanos JJ, Cray WC. Role of cholera toxin in enteric colonization by Vibrio cholerae O1 in rabbits. Infect. Immun.50(3), 813–816 (1985).
   PubMed Web of Science ®Google Scholar
• Taylor RK, Miller VL, Furlong DB, Mekalanos JJ. Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc. Natl Acad. Sci. USA84(9), 2833–2837 (1987).
   PubMed Web of Science ®Google Scholar
• Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, Levine MM. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J. Exp. Med.168(4), 1487–1492 (1988).
   PubMed Web of Science ®Google Scholar
• Sánchez J, Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell. Mol. Life Sci.65(9), 1347–1360 (2008).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Dhar U, Khan WA et al. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am. J. Trop. Med. Hyg.63(1–2), 12–20 (2000).
   PubMed Web of Science ®Google Scholar
• Nelson EJ, Chowdhury A, Harris J et al. Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea. Proc. Natl Acad. Sci. USA104(48), 19091–19096 (2007).
   PubMed Web of Science ®Google Scholar
• Darrow DC, Pratt EL. Disturbances of water and electrolytes in infantile diarrhea. Pediatrics3(2), 129–156 (1949).
   PubMed Web of Science ®Google Scholar
• Pierce NF, Banwell JG, Rupak DM et al. Effect of intragastric glucose-electrolyte infusion upon water and electrolyte balance in Asiatic cholera. Gastroenterology55(3), 333–343 (1968).
   PubMed Web of Science ®Google Scholar
• Hirschhorn N, Kinzie JL, Sachar DB et al. Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. N. Engl. J. Med.279(4), 176–181 (1968).
   PubMed Web of Science ®Google Scholar
• Nalin DR, Cash RA, Islam R, Molla M, Phillips RA. Oral maintenance therapy for cholera in adults. Lancet2(7564), 370–373 (1968).
   PubMed Web of Science ®Google Scholar
• Mahalanabis D, Choudhuri AB, Bagchi NG, Bhattacharya AK, Simpson TW. Oral fluid therapy of cholera among Bangladesh refugees. Johns Hopkins Med. J.132(4), 197–205 (1973).
   PubMedGoogle Scholar
• Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull. World Health Organ.36(6), 871–883 (1967).
   PubMed Web of Science ®Google Scholar
• Spira WM, Khan MU, Saeed YA, Sattar MA. Microbiological surveillance of intra-neighbourhood E1 Tor cholera transmission in rural Bangladesh. Bull. World Health Organ.58(5), 731–740 (1980).
   PubMed Web of Science ®Google Scholar
• Merrell DS, Butler SM, Qadri F et al. Host-induced epidemic spread of the cholera bacterium. Nature417(6889), 642–645 (2002).
   PubMed Web of Science ®Google Scholar
• Butler S, Nelson E, Chowdhury N, Faruque S, Calderwood S, Camilli A. Cholera stool bacteria repress chemotaxis to increase infectivity. Mol.Microbiol.60(2), 417–426 (2006).
   PubMed Web of Science ®Google Scholar
• Hartley DM, Morris JG, Smith DL. Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics?. PLoS Med.3(1), e7 (2006).
   PubMed Web of Science ®Google Scholar
• Cash RA, Music SI, Libonati JP, Craig JP, Pierce NF, Hornick RB. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J. Infect. Dis.130(4), 325–333 (1974).
   PubMed Web of Science ®Google Scholar
• Levine MM, Nalin DR, Craig JP et al. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg.73(1), 3–9 (1979).
   PubMed Web of Science ®Google Scholar
• Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. Duration of infection-derived immunity to cholera. J. Infect. Dis.143(6), 818–820 (1981).
   PubMed Web of Science ®Google Scholar
• Gangarosa EF, Beisel WR, Benyajati C, Sprinz H, Piyaratn P. The nature of the gastrointestinal lesion in asiatic cholera and its relation to pathogenesis: a biopsy study. Am. J. Trop. Med. Hyg.9, 125–135 (1960).
   PubMed Web of Science ®Google Scholar
• Qadri F, Bhuiyan TR, Dutta KK et al. Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut53(1), 62–69 (2004).
   PubMed Web of Science ®Google Scholar
• Flach C, Qadri F, Bhuiyan T et al. Broad up-regulation of innate defense factors during acute cholera. Infect. Immun.75(5), 2343–2350 (2007).
   PubMed Web of Science ®Google Scholar
• Mosley WH, Ahmad S, Benenson AS, Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull. World Health Organ.38(5), 777–785 (1968).
   PubMed Web of Science ®Google Scholar
• Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis.151(2), 236–242 (1985).
   PubMed Web of Science ®Google Scholar
• Finkelstein RA. Vibriocidal antibody inhibition (VAI) analysis: a technique for the identification of the predominant vibriocidal antibodies in serum and for the detection and identification of Vibrio cholerae antigens. J. Immunol.89, 264–271 (1962).
   Web of Science ®Google Scholar
• Neoh SH, Rowley D. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J. Infect. Dis.121(5), 505–513 (1970).
   PubMed Web of Science ®Google Scholar
• Burrows W, Mather AN. Studies on immunity to Asiatic cholera; the O and H antigenic structure of the cholera and related vibrios. J. Infect. Dis.79(2), 168–197 (1946).
   PubMed Web of Science ®Google Scholar
• Villeneuve S, Souchon H, Riottot MM et al. Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc. Natl Acad. Sci. USA97(15), 8433–8438 (2000).
   PubMed Web of Science ®Google Scholar
• Villeneuve S, Boutonnier A, Mulard LA, Fournier JM. Immunochemical characterization of an Ogawa–Inaba common antigenic determinant of Vibrio cholerae O1. Microbiology145(9), 2477–2484 (1999).
   PubMed Web of Science ®Google Scholar
• McCormack WM, Chakraborty J, Rahman AS, Mosley WH. Vibriocidal antibody in clinical cholera. J. Infect. Dis.120(2), 192–201 (1969).
   PubMed Web of Science ®Google Scholar
• Mosley WH, Aziz KM, Rahman AS, Chowdhury AK, Ahmed A. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh – three years of observation. Bull. World Health Organ.49(4), 381–387 (1973).
   PubMed Web of Science ®Google Scholar
• Bishop AL, Schild S, Patimalla B, Klein B, Camilli A. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by anti-lipopolysaccharide antibodies that inhibit bacterial motility. Infect. Immun.78(10), 4402–4420 (2010).
   PubMed Web of Science ®Google Scholar
• Koelle K, Pascual M, Yunus M. Serotype cycles in cholera dynamics. Proc. Biol. Sci.273(1603), 2879–2886 (2006).
   Google Scholar
• Ahmed A, Bhattacharjee AK, Mosley WH. Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas. J. Immunol.105, 431–441 (1970).
   PubMed Web of Science ®Google Scholar
• Merritt CB, Sack RB. Sensitivity of agglutinating and vibriocidal antibodies to 2-mercaptoethanol in human cholera. J. Infect. Dis.121(Suppl. 121), S25–S30 (1970).
   PubMed Web of Science ®Google Scholar
• Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hällgren R. Enhanced local production of complement components in the small intestines of patients with Crohn’s disease. N. Engl. J. Med.322(19), 1345–1349 (1990).
   PubMed Web of Science ®Google Scholar
• Ogundele MO. Role and significance of the complement system in mucosal immunity: particular reference to the human breast milk complement. Immunol. Cell. Biol.79(1), 1–10 (2001).
   PubMed Web of Science ®Google Scholar
• McCleery JL, Kraft SC, Rothberg RM. Demonstration of antibody in rabbit feces after active or passive parenteral immunization. Digestion3(4), 213–221 (1970).
   PubMed Web of Science ®Google Scholar
• Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature337(6203), 184–187 (1989).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Claypool SM, Wagner JS et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity20(6), 769–783 (2004).
   PubMed Web of Science ®Google Scholar
• Maaser C, Housley MP, Iimura M et al. Clearance of Citrobacter rodentium requires B cells but not secretory immunoglobulin A (IgA) or IgM antibodies. Infect. Immun.72(6), 3315–3324 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kobayashi K, Kuo TT et al. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J. Clin. Invest.116(8), 2142–2151 (2006).
   PubMed Web of Science ®Google Scholar
• Masuda A, Yoshida M, Shiomi H et al. Fcg receptor regulation of Citrobacter rodentium infection. Infect. Immun.76(4), 1728–1737 (2008).
   PubMed Web of Science ®Google Scholar
• Tomasi TB. Structure and function of mucosal antibodies. Annu. Rev. Med.21, 281–298 (1970).
   PubMed Web of Science ®Google Scholar
• Strugnell RA, Wijburg OLC. The role of secretory antibodies in infection immunity. Nat. Rev. Microbiol.8(9), 656 (2010).
   PubMed Web of Science ®Google Scholar
• Apter FM, Michetti P, Winner LS, Mack JA, Mekalanos JJ, Neutra MR. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect. Immun.61(12), 5279–5285 (1993).
   PubMed Web of Science ®Google Scholar
• Harris JB, LaRocque RC, Chowdhury F et al. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl. Trop. Dis.2(4), e221 (2008).
   PubMed Web of Science ®Google Scholar
• Harris AM, Bhuiyan MS, Chowdhury F et al. Antigen specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect. Immun.77(9), 3850–3856 (2009).
   PubMed Web of Science ®Google Scholar
• Benenson AS, Joseph PR, Oseasohn RO. Cholera vaccine field trials in east Pakistan. 1. Reaction and antigenicity studies. Bull. World Health Organ.38(3), 347–357 (1968).
   PubMed Web of Science ®Google Scholar
• Svennerholm AM, Hanson LA, Holmgren J, Lindblad BS, Nilsson B, Quereshi F. Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect. Immun.30(2), 427–430 (1980).
   PubMed Web of Science ®Google Scholar
• Elson CO, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol.132(6), 2736–2741 (1984).
   PubMed Web of Science ®Google Scholar
• Black RE, Levine MM, Clements ML, Young CR, Svennerholm AM, Holmgren J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun.55(5), 1116–1120 (1987).
   PubMed Web of Science ®Google Scholar
• Hanne LF, Finkelstein RA. Characterization and distribution of the hemagglutinins produced by Vibrio cholerae. Infect. Immun.36(1), 209–214 (1982).
   PubMed Web of Science ®Google Scholar
• Clemens J. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet335(8684), 270–273 (1990).
   PubMed Web of Science ®Google Scholar
• van Loon FP, Clemens JD, Chakraborty J et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine14(2), 162–166 (1996).
   PubMed Web of Science ®Google Scholar
• Berstad AK, Holst J, Frøholm LO et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J. Med. Microbiol.49(2), 157–163 (2000).
   PubMed Web of Science ®Google Scholar
• Berstad AK, Oftung F, Korsvold GE et al. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine. Vaccine18(22), 2323–2330 (2000).
   PubMed Web of Science ®Google Scholar
• Jonson G, Holmgren J, Svennerholm AM. Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1. Microb. Pathog.11(3), 179–188 (1991).
   PubMed Web of Science ®Google Scholar
• Albert MJ. Vibrio cholerae O139 Bengal. J. Clin. Microbiol.32(10), 2345–2349 (1994).
   PubMed Web of Science ®Google Scholar
• Glass RI, Becker S, Huq MI et al. Endemic cholera in rural Bangladesh, 1966–1980. Am. J. Epidemiol.116(6), 959–970 (1982).
   PubMed Web of Science ®Google Scholar
• Nair GB, Faruque SM, Bhuiyan NA, Kamruzzaman M, Siddique AK, Sack DA. New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. J. Clin. Microbiol.40(9), 3296–3299 (2002).
   PubMed Web of Science ®Google Scholar
• Faruque SM, Chowdhury N, Kamruzzaman M et al. Reemergence of epidemic Vibrio cholerae O139, Bangladesh. Emerg. Infect. Dis.9(9), 1116–1122 (2003).
   PubMed Web of Science ®Google Scholar
• Owen RL, Pierce NF, Apple RT, Cray WC. M cell transport of Vibrio cholerae from the intestinal lumen into Peyer’s patches: a mechanism for antigen sampling and for microbial transepithelial migration. J. Infect. Dis.153(6), 1108–1118 (1986).
   PubMed Web of Science ®Google Scholar
• Pierce NF, Cray WC, Kaper JB, Mekalanos JJ. Determinants of immunogenicity and mechanisms of protection by virulent and mutant Vibrio cholerae O1 in rabbits. Infect. Immun.56(1), 142–148 (1988).
   PubMed Web of Science ®Google Scholar
• Nygren E, Holmgren J, Attridge SR. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae. Vaccine26, 6784–6790 (2008).
   PubMed Web of Science ®Google Scholar
• Pierce NF, Kaper JB, Mekalanos JJ, Cray WC, Richardson K. Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine. Infect. Immun.55(2), 477–481 (1987).
   PubMed Web of Science ®Google Scholar
• Honda T, Finkelstein RA. Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin. Proc. Natl Acad. Sci. USA76(4), 2052–2056 (1979).
   PubMed Web of Science ®Google Scholar
• Levine MM, Black RE, Clements ML et al. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect. Immun.43(2), 515–522 (1984).
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Herrington D et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet2(8609), 467–470 (1988).
   PubMed Web of Science ®Google Scholar
• Simanjuntak CH, O’Hanley P, Punjabi NH et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J. Infect. Dis.168(5), 1169–1176 (1993).
   PubMed Web of Science ®Google Scholar
• Cryz SJ, Levine MM, Kaper JB, Fürer E, Althaus B. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine8(6), 577–580 (1990).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis.166(4), 837–841 (1992).
   PubMed Web of Science ®Google Scholar
• Suharyono, Simanjuntak C, Witham N et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5–9-year-old Indonesian children. Lancet340(8821), 689–694 (1992).
   PubMed Web of Science ®Google Scholar
• Richie EE, Punjabi NH, Sidharta YY et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine18(22), 2399–2410 (2000).
   PubMed Web of Science ®Google Scholar
• Calain P, Chaine J-P, Johnson E et al. Can oral cholera vaccination play a role in controlling a cholera outbreak?. Vaccine22(19), 2444–2451 (2004).
   PubMed Web of Science ®Google Scholar
• Michalski J, Galen JE, Fasano A, Kaper JB. CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain. Infect. Immun.61(10), 4462–4468 (1993).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP et al. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a Δ ctxA Δ zot Δ ace derivative of El Tor Ogawa Vibrio cholerae. J. Infect. Dis.168(6), 1536–1540 (1993).
   PubMed Web of Science ®Google Scholar
• Silva TM, Schleupner MA, Tacket CO et al. New evidence for an inflammatory component in diarrhea caused by selected new, live attenuated cholera vaccines and by El Tor and O139 Vibrio cholerae. Infect. Immun.64(6), 2362–2364 (1996).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Kotloff KL, Losonsky G et al. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am. J. Trop. Med. Hyg.56(5), 533–537 (1997).
   PubMed Web of Science ®Google Scholar
• Fullner K. The contribution of accessory toxins of Vibrio cholerae O1 El Tor to the proinflammatory response in a murine pulmonary cholera model. J. Exp. Med.195(11), 1455–1462 (2002).
   PubMed Web of Science ®Google Scholar
• Lin W, Fullner KJ, Clayton R et al. Identification of a Vibrio cholerae RTX toxin gene cluster that is tightly linked to the cholera toxin prophage. Proc. Natl Acad. Sci. USA96(3), 1071–1076 (1999).
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Herrington D et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect. Immun.56(1), 161–167 (1988).
   PubMed Web of Science ®Google Scholar
• Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol. Lett.111(1), 15–21 (1993).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Tacket CO, Losonsky G et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun.65(9), 3852–3856 (1997).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Nataro JP et al. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J. Infect. Dis.172(3), 883–886 (1995).
   PubMed Web of Science ®Google Scholar
• Kenner JR, Coster TS, Taylor DN et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J. Infect. Dis.172(4), 1126–1129 (1995).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Killeen KP, Hack DC et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J. Infect. Dis.170(6), 1518–1523 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen MB, Giannella RA, Bean J et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect. Immun.70(4), 1965–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J. Infect. Dis.192(4), 573–579 (2005).
   PubMed Web of Science ®Google Scholar
• Qadri F, Chowdhury MI, Faruque SM et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine25(2), 231–238 (2007).
   PubMed Web of Science ®Google Scholar
• Coster TS, Killeen KP, Waldor MK et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet345(8955), 949–952 (1995).
   PubMed Web of Science ®Google Scholar
• Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J. Infect. Dis.169(3), 709–710 (1994).
   PubMed Web of Science ®Google Scholar
• Albert MJ, Alam K, Ansaruzzaman M, Qadri F, Sack RB. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR. J. Infect. Dis.169(1), 230–231 (1994).
   PubMed Web of Science ®Google Scholar
• Svennerholm AM, Holmgren J. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect. Immun.13(3), 735–740 (1976).
   PubMed Web of Science ®Google Scholar
• Peterson JW. Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine. Infect. Immun.26(2), 528–533 (1979).
   PubMed Web of Science ®Google Scholar
• Pierce NF, Kaniecki EA, Northrup RS. Protection against experimental cholera by antitoxin. J. Infect. Dis.126(6), 606–616 (1972).
   PubMed Web of Science ®Google Scholar
• Chatterjee SN, Das J. Electron microscopic observations on the excretion of cell-wall material by Vibrio cholerae. J. Gen. Microbiol.49(1), 1–11 (1967).
   PubMedGoogle Scholar
• Eubanks ER, Guentzel MN, Berry LJ. Evaluation of surface components of Vibrio cholerae as protective immunogens. Infect. Immun.15(2), 533–538 (1977).
   PubMed Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N. Engl. J. Med.362(16), 1511–1520 (2010).
   PubMed Web of Science ®Google Scholar
• Schild S, Nelson EJ, Camilli A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect. Immun.76(10), 4554–4563 (2008).
   PubMed Web of Science ®Google Scholar
• Schild S, Nelson EJ, Bishop AL, Camilli A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect. Immun.77(1), 472–484 (2009).
   PubMed Web of Science ®Google Scholar
• Acevedo R, Callicó A, Campo JD et al. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods49(4), 309–315 (2009).
   PubMed Web of Science ®Google Scholar
• Mann JF, Acevedo R, Campo JD, Perez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?. Expert Rev. Vaccines8(1), 103–112 (2009).
   PubMed Web of Science ®Google Scholar
• Chaicumpa W, Parairo JR, New RC et al. Immunogenicity of liposome-associated oral cholera vaccine prepared from combined Vibrio cholerae antigens. Asian Pac. J. Allergy Immunol.8(2), 87–94 (1990).
   PubMed Web of Science ®Google Scholar
• Kalambaheti T, Chaisri U, Srimanote P, Pongponratn E, Chaicumpa W. Immunogenicity and protective role of three formulations of oral cholera vaccine. Vaccine16(2–3), 201–207 (1998).
   PubMed Web of Science ®Google Scholar
• Chandrasekhar U, Sinha S, Bhagat HR, Sinha VB, Srivastava BS. Comparative efficacy of biodegradable liposomes and microspheres as carriers for delivery of Vibrio cholerae antigens in the intestine. Vaccine12(15), 1384–1388 (1994).
   PubMed Web of Science ®Google Scholar
• Eko FO, Schukovskaya T, Lotzmanova EY et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine21(25–26), 3663–3674 (2003).
   PubMed Web of Science ®Google Scholar
• Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev. Vaccines2(1), 45–51 (2003).
   PubMedGoogle Scholar
• Kadurugamuwa JL, Beveridge TJ. Delivery of the non-membrane-permeative antibiotic gentamicin into mammalian cells by using Shigella flexneri membrane vesicles. Antimicrob. Agents Chemother.42(6), 1476–1483 (1998).
   PubMed Web of Science ®Google Scholar
• Fiocca R, Necchi V, Sommi P et al. Release of Helicobacter pylori vacuolating cytotoxin by both a specific secretion pathway and budding of outer membrane vesicles. Uptake of released toxin and vesicles by gastric epithelium. J. Pathol.188(2), 220–226 (1999).
   PubMed Web of Science ®Google Scholar
• Bauman SJ, Kuehn MJ. Pseudomonas aeruginosa vesicles associate with and are internalized by human lung epithelial cells. BMC Microbiol.9, 26 (2009).
   PubMed Web of Science ®Google Scholar
• Ali M, Emch M, Von Seidlein L et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet366(9479), 44–49 (2005).
   PubMed Web of Science ®Google Scholar
• Longini IM, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med.4(11), e336 (2007).
   PubMed Web of Science ®Google Scholar
• Lopez AL, Clemens JD, Deen J, Jodar L. Cholera vaccines for the developing world. Hum. Vaccin.4(2), 165–169 (2008).
   PubMed Web of Science ®Google Scholar
• Cumberland S. An old enemy returns. Bull. World Health Organ.87(2), 85–86 (2009).
   PubMed Web of Science ®Google Scholar
• Thiem VD, Deen JL, Von Seidlein L et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine24(20), 4297–4303 (2006).
   PubMed Web of Science ®Google Scholar
• Trach DD, Clemens JD, Ke NT et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet349(9047), 231–235 (1997).
   PubMed Web of Science ®Google Scholar
• Trach DD, Cam PD, Ke NT et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Vietnam. Bull. World Health Organ.80(1), 2–8 (2002).
   PubMed Web of Science ®Google Scholar
• Anh DD, Canh doG, Lopez A et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine25(6), 1149–1155 (2007).
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the Production and Control of Inactivated Oral Cholera Vaccines. WHO Expert Committee on Biological Standardization: Fifty-second report. Annex 3. WHO, Geneva, Switzerland, 129–149 (2004).
   Google Scholar
• Mahalanabis D, Lopez AL, Sur D et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS ONE3(6), e2323 (2008).
   PubMed Web of Science ®Google Scholar
• Kanungo S, Paisley A, Lopez AL et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine27(49), 6887–6893 (2009).
   PubMed Web of Science ®Google Scholar
• Sur D, Lopez AL, Kanungo S et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet374(9702), 1694–1702 (2009).
   PubMed Web of Science ®Google Scholar
• Deb BC, Sircar BK, Sengupta PG et al. Studies on interventions to prevent eltor cholera transmission in urban slums. Bull. World Health Organ.64(1), 127–131 (1986).
   PubMed Web of Science ®Google Scholar
• Colwell RR, Huq A, Islam MS et al. Reduction of cholera in Bangladeshi villages by simple filtration. Proc. Natl Acad. Sci. USA100(3), 1051–1055 (2003).
   PubMed Web of Science ®Google Scholar
• Chen D, Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev. Vaccines8(5), 547–557 (2009).
   PubMed Web of Science ®Google Scholar
• Lucas MES, Deen JL, Von Seidlein L et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N. Engl. J. Med.352(8), 757–767 (2005).
   PubMed Web of Science ®Google Scholar
• Perry RT, Plowe CV, Koumaré B et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ.76(1), 63–71 (1998).
   PubMed Web of Science ®Google Scholar
• Chen DJ, Osterrieder N, Metzger SM et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl Acad. Sci. USA107(7), 3099–3104 (2010).
   PubMed Web of Science ®Google Scholar
• Eko F, Lubitz W, McMillan L et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine21(15), 1694–1703 (2003).
   PubMed Web of Science ®Google Scholar
• Ryan E, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. Expert Rev. Vaccines5(4), 483–494 (2006).
   PubMed Web of Science ®Google Scholar
• Jelinek T, Kollaritsch H. Vaccination with Dukoral against travelers’ diarrhea (ETEC) and cholera. Expert Rev. Vaccines7(5), 561–567 (2008).
   PubMed Web of Science ®Google Scholar
• Deen JL, Von Seidlein L, Sur D et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl. Trop. Dis.2(2), e173 (2008).
   PubMed Web of Science ®Google Scholar
• Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet374(9694), 1032–1035 (2009).
   PubMed Web of Science ®Google Scholar
• Albert MJ, Qadri F, Wahed MA et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J. Infect. Dis.187(6), 909–913 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmed T, Svennerholm AM, Al Tarique A, Sultana GN, Qadri F. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Vaccine27(9), 1433–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Gunn RA, Kimball AM, Pollard RA et al. Bottle feeding as a risk factor for cholera in infants. Lancet2(8145), 730–732 (1979).
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR et al. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am. J. Epidemol.131(3), 400–411 (1990).
   PubMed Web of Science ®Google Scholar
• Newburg D, Ruiz-Palacios G, Morrow A. Human milk glycans protect infants against enteric pathogens. Annu. Rev. Nutr.25, 37–58 (2005).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Svennerholm AM, Lindblad M. Receptor-like glycocompounds in human milk that inhibit classical and El Tor Vibrio cholerae cell adherence (hemagglutination). Infect. Immun.39(1), 147–154 (1983).
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Chakraborty J et al. Field trial of oral cholera vaccines in Bangladesh: evaluation of anti-bacterial and anti-toxic breast-milk immunity in response to ingestion of the vaccines. Vaccine8(5), 469–472 (1990).
   PubMed Web of Science ®Google Scholar
• Jertborn M, Svennerholm AM, Holmgren J. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J. Clin. Microbiol.24(2), 203–209 (1986).
   PubMed Web of Science ®Google Scholar
• Saroso JS, Bahrawi W, Witjaksono H et al. A controlled field trial of plain and aluminium hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia, during 1973–75. Bull. World Health Organ.56(4), 619–627 (1978).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Szu SC, Finkelstein RA, Robbins JB. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect. Immun.60(8), 3201–3208 (1992).
   PubMed Web of Science ®Google Scholar
• Kossaczka Z, Shiloach J, Johnson V et al.Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect. Immun.68(9), 5037–5043 (2000).
   PubMed Web of Science ®Google Scholar
• Boutonnier A, Villeneuve S, Nato F, Dassy B, Fournier JM. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Infect. Immun.69(5), 3488–3493 (2001).
   PubMed Web of Science ®Google Scholar
• Chernyak A, Kondo S, Wade TK et al. Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J. Infect. Dis.185(7), 950–962 (2002).
   PubMed Web of Science ®Google Scholar
• Czerkinsky C, Holmgren J. Topical immunization strategies. Mucosal Immunol.3, 545–555 (2010).
   PubMed Web of Science ®Google Scholar
• Rollenhagen JE, Kalsy A, Saksena R et al. Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice. Vaccine27(36), 4917–4922 (2009).
   PubMed Web of Science ®Google Scholar
• Katial RK, Brandt BL, Moran EE, Marks S, Agnello V, Zollinger WD. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun.70(2), 702–707 (2002).
   PubMed Web of Science ®Google Scholar
• Haneberg B, Holst J. Can nonliving nasal vaccines be made to work?. Expert Rev. Vaccines1(2), 227–232 (2002).
   PubMedGoogle Scholar
• van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol.165(9), 4778–4782 (2000).
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med.350(9), 896–903 (2004).
   PubMed Web of Science ®Google Scholar
• Rudin A, Johansson EL, Bergquist C, Holmgren J. Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect. Immun.66(7), 3390–3396 (1998).
   PubMed Web of Science ®Google Scholar
• Sengupta DK, Sengupta TK, Ghose AC. Antibodies to outer membrane proteins of Vibrio cholerae induce protection by inhibition of intestinal colonization of vibrios. FEMS Microbiol. Immunol.4(5), 261–266 (1992).
   PubMedGoogle Scholar
• Weil AA, Arifuzzaman M, Bhuiyan TR et al. Memory T cell responses to Vibrio cholerae O1 infection. Infect. Immun.5090–5096 (2009).
   PubMed Web of Science ®Google Scholar
• Hang L, John M, Asaduzzaman M et al. Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae. Proc. Natl Acad. Sci. USA100(14), 8508–8513 (2003).
   PubMed Web of Science ®Google Scholar
• Larocque R, Krastins B, Harris J et al. Proteomic analysis of Vibrio cholerae in human stool. Infect. Immun.76(9), 4145–4151 (2008).
   PubMed Web of Science ®Google Scholar
• Sun DX, Mekalanos JJ, Taylor RK. Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model. J. Infect. Dis.161(6), 1231–1236 (1990).
   PubMed Web of Science ®Google Scholar
• Sun DX, Seyer JM, Kovari I, Sumrada RA, Taylor RK. Localization of protective epitopes within the pilin subunit of the Vibrio cholerae toxin-coregulated pilus. Infect. Immun.59(1), 114–118 (1991).
   PubMed Web of Science ®Google Scholar
• Asaduzzaman M, Ryan E, John M et al. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139. Infect. Immun.72(8), 4448–4454 (2004).
   PubMed Web of Science ®Google Scholar
• Wu JY, Wade WF, Taylor RK. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect. Immun.69(12), 7695–7702 (2001).
   PubMed Web of Science ®Google Scholar
• Meeks MD, Wade TK, Taylor RK, Wade WF. Immune response genes modulate serologic responses to Vibrio cholerae TcpA pilin peptides. Infect. Immun.69(12), 7687–7694 (2001).
   PubMed Web of Science ®Google Scholar